Abbvie Inc
NYSE:ABBV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
154.62
203.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Abbvie Inc
Wall Street
Price Targets
ABBV Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for
ABBV
is 210.06 USD
with a low forecast of 166.65 USD and a high forecast of 252 USD.
ABBV Last Price Targets
Abbvie Inc
The latest public price target was made on Nov 12, 2024 by
Evan David Seigerman
from
BMO Capital
,
who expects
ABBV
stock to
rise by 18%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Evan David Seigerman
BMO Capital
|
208
USD
Upside 18% |
1 month ago
Nov 12, 2024
|
Abbvie (ABBV) PT Lowered to $208 at BMO Capital
StreetInsider
|
Geoff Meacham
Citigroup
|
226
USD
Upside 29% |
1 month ago
Oct 31, 2024
|
AbbVie price target raised to $226 from $215 at Citi
TheFly
|
|
Evan David Seigerman
BMO Capital
|
228
USD
Upside 30% |
1 month ago
Oct 31, 2024
|
Abbvie (ABBV) PT Raised to $228 at BMO Capital
StreetInsider
|
Charlie Yang
Bank of America Securities
|
210
USD
Upside 20% |
1 month ago
Oct 31, 2024
|
AbbVie price target raised to $210 from $195 at BofA
TheFly
|
|
Geoff Meacham
Bank of America Securities
|
195
USD
Upside 11% |
2 months ago
Oct 18, 2024
|
Abbvie (ABBV) PT Raised to $195 at BofA Securities
StreetInsider
|
Courtney Breen
Bernstein
|
203
USD
Upside 16% |
2 months ago
Oct 17, 2024
|
AbbVie initiated with a Market Perform at Bernstein
TheFly
|
Christopher Raymond
Raymond James
|
209
USD
Upside 19% |
3 months ago
Aug 23, 2024
|
Abbvie (ABBV) PT Raised to $209 at Piper Sandler
StreetInsider
|
|
Evan Seigerman
BMO Capital
|
214
USD
Upside 22% |
5 months ago
Jul 19, 2024
|
AbbVie price target raised to $214 from $180 at BMO Capital
TheFly
|
|
Christopher Raymond
Raymond James
|
190
USD
Upside 8% |
6 months ago
Jun 18, 2024
|
Abbvie (ABBV) PT Raised to $190 at Piper Sandler
StreetInsider
|
Rajesh Kumar
HSBC
|
185
USD
Upside 5% |
6 months ago
Jun 5, 2024
|
HSBC Upgrades Abbvie (ABBV) to Buy
StreetInsider
|
James Shin
Deutsche Bank
|
175
USD
Downside 0% |
6 months ago
May 24, 2024
|
Deutsche Bank Reiterates Hold Rating on Abbvie (ABBV)
StreetInsider
|
|
Louise Chen
Cantor Fitzgerald
|
200
USD
Upside 14% |
7 months ago
May 17, 2024
|
Cantor Fitzgerald Starts Abbvie (ABBV) at Overweight
StreetInsider
|
|
Evan Seigerman
BMO Capital
|
180
USD
Upside 3% |
7 months ago
Apr 29, 2024
|
AbbVie price target lowered to $180 from $195 at BMO Capital
TheFly
|
Carter Gould
Barclays
|
195
USD
Upside 11% |
8 months ago
Mar 27, 2024
|
Abbvie (ABBV) PT Raised to $195 at Barclays
StreetInsider
|
|
Christopher Raymond
Raymond James
|
170
USD
Downside 3% |
1 year ago
Nov 9, 2023
|
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
Benzinga
|
|
Gary Nachman
Raymond James
|
177
USD
Upside 1% |
1 year ago
Sep 29, 2023
|
AbbVie's Promising Leap Towards Long-Term Growth: Analyst
Benzinga
|
Vamil Divan
Guggenheim
|
171
USD
Downside 3% |
1 year ago
May 9, 2023
|
Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts
Benzinga
|
|
Unknown Analyst
BMO Capital
|
167
USD
Downside 5% |
1 year ago
Feb 6, 2023
|
BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $167
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ABBV's stock price target?
Price Target
210.06
USD
According to Wall Street analysts, the average 1-year price target for
ABBV
is 210.06 USD
with a low forecast of 166.65 USD and a high forecast of 252 USD.
What is Abbvie Inc's Revenue forecast?
Projected CAGR
6%
For the last 8 years the
compound annual growth rate for
Abbvie Inc's revenue is
11%.
The projected
CAGR
for the next 4 years is
6%.
What is Abbvie Inc's Operating Income forecast?
Projected CAGR
20%
For the last 8 years the
compound annual growth rate for
Abbvie Inc's operating income is
10%.
The projected
CAGR
for the next 4 years is
20%.
What is Abbvie Inc's Net Income forecast?
Projected CAGR
54%
For the last 8 years the
compound annual growth rate for
Abbvie Inc's net income is
-1%.
The projected
CAGR
for the next 4 years is
54%.
You don't have any saved screeners yet
